Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thiogenesis TherapeuticsFRA:Q8M 20 Net-Net Working Capital is €0.06 as of Jun. 2026. GuruFocus rates FRA:Q8M with a GF Score™ of 20/100. The stock has 1 warning sign investors should review. Among 838 Biotechnology companies, Thiogenesis Therapeutics ranks worse than 54.89% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Thiogenesis Therapeutics's Net-Net Working Capital for the quarter that ended in Jun. 2026 was €0.06.
The industry rank for Thiogenesis Therapeutics's Net-Net Working Capital or its related term are showing as below:
FRA:Q8M's Price-to-Net-Net-Working-Capital is ranked worse than 54.89% of 838
companies
in the Biotechnology industry
Industry Median: 5.36
vs FRA:Q8M: 5.50
Thiogenesis Therapeutics (FRA:Q8M) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Thiogenesis Therapeutics Net-Net Working Capital Related Terms
Thiogenesis Therapeutics Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Thiogenesis Therapeutics's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thiogenesis Therapeutics Net-Net Working Capital Chart
FRA:Q8M vs VRTX, REGN, MRNA: Net-Net Working Capital Comparison
For the Biotechnology subindustry, Thiogenesis Therapeutics's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thiogenesis Therapeutics Price-to-Net-Net-Working-Capital vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Thiogenesis Therapeutics's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of €0.06 mean?
Thiogenesis Therapeutics (FRA:Q8M) has a Net-Net Working Capital of €0.06 as of Jun. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Thiogenesis Therapeutics According to the industry distribution chart, Thiogenesis Therapeutics ranks #460 out of 838 companies in the Biotechnology industry, placing it in the top 54.9%.
Is Thiogenesis Therapeutics' Net-Net Working Capital too high?
Thiogenesis Therapeutics' current Net-Net Working Capital is €0.06. Based on the distribution chart, Thiogenesis Therapeutics ranks #460 out of 838 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Thiogenesis Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Thiogenesis Therapeutics' Net-Net Working Capital compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thiogenesis Therapeutics ranks #460 out of 838 companies for Net-Net Working Capital. This places Thiogenesis Therapeutics in the lower half of its industry. The industry median Net-Net Working Capital is 5.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.36, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Thiogenesis Therapeutics For the Biotechnology industry, the median Net-Net Working Capital is 5.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thiogenesis Therapeutics's current Net-Net Working Capital is €0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thiogenesis Therapeutics stock overvalued right now?
Thiogenesis Therapeutics (FRA:Q8M) has a current Net-Net Working Capital of €0.06. The current Net-Net Working Capital is €0.06. Thiogenesis Therapeutics' overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Thiogenesis Therapeutics (FRA:Q8M), the current Net-Net Working Capital is €0.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also conducting research and clinical development activities for primary mitochondrial diseases, including Leigh syndrome spectrum disorders.
20GF Score
Get the complete analysis for FRA:Q8M
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Q8M has been successfully added to your 
